BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2498043)

  • 1. Pseudomonas aeruginosa: in vivo (murine) activity of five antimicrobial drugs, with and without human IgG immunoglobulin preparations.
    Traub WH; Bauer D; Spohr M
    Chemotherapy; 1989; 35(1):23-38. PubMed ID: 2498043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
    Collins MS; Hector RF; Roby RE; Edwards AA; Ladehoff DK; Dorsey JH
    Infection; 1987; 15 Suppl 2():S51-9. PubMed ID: 3112021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa: in vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated human blood.
    Traub WH; Spohr M; Bauer D
    Chemotherapy; 1988; 34(4):284-97. PubMed ID: 3145172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of gram-negative and gram-positive infections using 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection using intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
    Collins MS; Hector RF; Roby RE; Edwards AA; Ladehoff DK; Dorsey JH
    Infection; 1987; 15(1):60-8. PubMed ID: 3570485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM; Johnson DM; Jones RN
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model.
    Gudmundsson S; Einarsson S; Erlendsdottir H; Moffat J; Bayer W; Craig WA
    J Antimicrob Chemother; 1993 May; 31 Suppl D():177-91. PubMed ID: 8335520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
    Kádár B; Szász M; Kristóf K; Pesti N; Krizsán G; Szentandrássy J; Rókusz L; Nagy K; Szabó D
    Acta Microbiol Immunol Hung; 2010 Sep; 57(3):235-45. PubMed ID: 20870595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance of Pseudomonas aeruginosa strains isolated from surgical infections in a 7-year period at a general hospital in Venezuela.
    Rodriguez CN; Rodriguez-Morales AJ; Garcia A; Pastran B; Meijomil P
    Surg Infect (Larchmt); 2006 Jun; 7(3):269-73. PubMed ID: 16875460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice.
    Shimizu M; Katoh H; Hamaoka S; Kinoshita M; Akiyama K; Naito Y; Sawa T
    J Infect Chemother; 2016 Apr; 22(4):240-7. PubMed ID: 26867796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria.
    Strateva T; Ouzounova-Raykova V; Markova B; Todorova A; Marteva-Proevska Y; Mitov I
    J Chemother; 2007 Apr; 19(2):140-5. PubMed ID: 17434821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.